Lessons from the deconstruction of Amgen
Amgen, once a darling of the biotechnology industry, apparently has become a victim of its own success and perhaps an excess of legal maneuvering, according to MedTech Futures columnist Ogan Gurel. The company recently announced the layoff of 2,600 workers, about 14 percent of its...